Tests SCG142 cell therapy for advanced HPV-linked cancers
Tests SCG142 modified immune cells in adults with advanced HPV-linked cancers.
Plain-language title generated from the registry record
Registry title: SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas
Key facts
- Where
- Qingdao, ChinaSee the site
- Phase
- Phase 1
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced cancer linked to human papillomavirus (HPV), who have at least one tumor that can be measured and who are fairly active in daily life. It tests SCG142 TCR-T cells.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- HPV-associated carcinomas with at least one measurable lesion (RECIST 1.1). The title says advanced disease.
- Biomarker or test result
- HPV-associated carcinoma (the record gives no other test result)
Main reasons for not taking part
- Active or uncontrollable infections or other active major illnesses of the heart or lungs
- Active autoimmune disease
- Known active Hepatitis B or Hepatitis C
- Other severe medical conditions that may limit taking part
Read by machine on 9 November 2026.
Where in China
- The Affiliated Hosptial of Qingdao UniversityQingdao, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The Affiliated Hospital of Qingdao University
- Trial code
- NCT06544720
- Record updated
- 9 August 2024
- Original description
A multicenter, open, single arm dose escalation and dose expansion phase I study to evaluate the safety, tolerability, and efficacy of SCG142 TCR-T cells in Subjects with advanced HPV associated carcinomas.Read full original descriptionShow less
A Phase 1 Clinical Study of Autologous TCR-T Cells (SCG142) Therapy for Advanced HPV Associated Carcinomas
A multicenter, open, single arm dose escalation and dose expansion phase I study to evaluate the safety, tolerability, and efficacy of SCG142 TCR-T cells in Subjects with advanced HPV associated carcinomas.
Inclusion: Greater than or equal to 18 years of age; HPV associated carcinomas; Patients must have at least one measurable lesion defined by RECIST 1.1; Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
Exclusion: Active or uncontrollable infections or other active major medical illnesses of the cardiovascular, respiratory; Patients with active autoimmune diseases; Patient has a known active Hepatitis B or Hepatitis C; Other severe medical conditions that may limit subject\'s participation in this trial.